NEWNAN, Ga., Oct. 6 /PRNewswire/ -- The authors of a newly published paper in the September/October journal Vascular Disease Management conclude that the micro-bland embolization technique possible with Embozene(TM) Color-Advanced Microspheres leads to better clinical outcomes. Franco Orsi, MD, PhD, and colleagues at the European Institute of Oncology (EIO) in Rome conclude that small, tightly calibrated Embozene(TM) Microspheres are better than other products for the treatment of liver cancer and metastases. The group at EIO has developed a technique to cut off the blood supply deep within the tumor bed of primary and metastatic liver tumors that leads to effective tumor control and reduced recurrence of tumors without the use of chemotherapy drugs. As the authors say, "The dimension and shape of embolic particles seem to be the most important characteristics for this aim."
"We are pleased that Dr. Orsi has pioneered this embolization technique which we call Micro-Bland(TM) embolization made possible due to the unique and very precise calibration of Embozene(TM) Microspheres. We are gratified that he has demonstrated that this technique using CeloNova's Embozene(TM) leads to superior clinical findings in the treatment of liver cancer," said Thomas A. Gordy, President and Chief Executive Officer, CeloNova Biosciences. Embozene(TM) Microspheres, unlike other embolics, are precision shaped and sized so that larger spheres allow the deepest possible penetration of tumors. Patients with liver cancer treated in this new way can experience a longer life and a better quality of life.
"Embolic particles should be size-calibrated with a small bandwidth in diameter variations because during administration, larger particles within the same vial or syringe may occlude micro-vessels more proximally and prevent a deeper penetration of the smaller ones," reports Professor Orsi.
About Embozene(TM) Microspheres
Embozene(TM) Microspheres are the first and only microspheres to be color-enhanced with a different color for each size for increased procedural safety, efficiency, and visibility. They are also available in a wider range of sizes than any other spherical embolic on the market. CeloNova's Embozene(TM) Microspheres consist of a hydrogel core and an exterior shell made from Polyzene(R)-F, CeloNova's proprietary, anti-inflammatory, and bacterial-resistant polymer. Four design features distinguish Embozene(TM) Microspheres from other spherical embolics: biocompatibility, precise calibration, stable suspension, and structural stability.
About CeloNova BioSciences, Inc.
Headquartered in Newnan, Georgia, CeloNova BioSciences, Inc., is a developer of novel medical devices that are enhanced by one of the Company's proprietary materials, Polyzene(R)-F, a highly lubricious, anti-thrombotic, anti-inflammatory, and bacterial-resistant making it an ideal surface treatment for implanted medical devices. The Company's current products include Embozene(TM) Color-Advanced Microspheres and the CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F. For more information, please visit www.celonova.com.
SOURCE CeloNova BioSciences, Inc.
CONTACT: Teresa Wilson of CeloNova BioSciences, Inc., +1-678-895-6486 or
Web site: http://www.celonova.com/